Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Relapsed/Refractory AML and MDS Post-Transplant
NCT03600155Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2018
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Optimal dose of nivolumab in combination with ipilimumab. Started Oct 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03600155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600155.